Survodutide (BI 456906)

The downside is dominated by two things: an unfinished, investigational profile and a real tolerability problem. The dominant risk cluster is that survodutide is not approved anywhere, so the only access is grey-market material of unknown quality, and the safety record stops at about 76 weeks with no completed heart-outcomes trial. The most exposed people are those who escalate the dose too fast, where nausea and vomiting drove a 20% dropout in Phase 2, and anyone with a baseline heart-rhythm concern, given the glucagon-driven heart-rate rise. Most of these concerns are intrinsic to the drug and its early stage rather than interaction-driven. The one genuine bright spot on this side is reversibility: the drug clears cleanly when you stop.

Safety Risk (4.0/5.0): Safety risk sits at the class level because survodutide carries the pancreatitis potential common to GLP-1-based drugs, even though no clear signal showed in Phase 2, per Sanyal 2024. On top of that, the glucagon arm raises resting heart rate by a few beats per minute, and there is no completed cardiovascular outcomes trial to confirm long-term heart safety, per Dahl 2024. The class also carries a thyroid-tumor caution that applies here, per Le Roux 2024. None of these is a confirmed catastrophe at therapeutic doses, but the combination of a known class-level serious risk, an unproven heart profile, and grey-market sourcing keeps the worst-case safety concern firmly in the upper range.

Side Effect Profile (3.0/5.0): Side effects are common and front-loaded. In the Phase 2 liver trial, nausea hit about 66% of patients, diarrhea about 49%, and vomiting about 41%, far above placebo, per Sanyal 2024. Those gut effects drove a 20% discontinuation rate under the fast 24-week dose climb. The good news is that this profile is largely a titration problem. The Phase 3 trials used slower, flexible escalation specifically to cut the attrition, the same pattern seen when semaglutide and tirzepatide moved from Phase 2 to real-world use. Still, the early months are rough for a meaningful share of people.

Financial Cost (3.0/5.0): Cost is impossible to pin down because there is no legitimate channel. Survodutide is not sold by any pharmacy or manufacturer for use, so the only pricing is grey-market, where you pay for material of unverified identity and purity. That makes the real cost both the cash outlay and the hidden risk of getting something other than what you ordered. The score reflects a moderate-to-meaningful burden once you account for ongoing weekly dosing plus the testing any responsible user would run. Worth flagging: because the drug is investigational, there is no insurance pathway and no manufacturer assistance program, so every dollar is out of pocket, and there is no recourse if a vial turns out to be underdosed or mislabeled. That asymmetry, paying real money for unverifiable material, is a bigger practical cost than the headline price per milligram.

Time/Effort Burden (2.8/5.0): Effort is moderate. Survodutide is a once-weekly injection, which is far lighter than the daily peptides, and the weekly cadence is easy to remember. The friction comes from the slow titration schedule, the need to manage early nausea, cold-chain storage for the peptide, and the monitoring a thoughtful user would want for liver enzymes, glucose, and heart rate. None of that is heavy on its own, but together it is more involved than swallowing a pill, and the grey-market sourcing adds its own logistics.

Opportunity Cost (2.2/5.0): Opportunity cost is real because better-evidenced options exist for most goals. For weight loss, tirzepatide is approved and loses more, and for general metabolic support semaglutide is approved with cardiovascular outcome data behind it. Choosing investigational survodutide over an approved drug means trading proven efficacy and a known supply chain for a liver mechanism that has not yet finished proving itself. The exception is the fatty-liver-focused user, for whom survodutide's direct hepatic action is genuinely differentiated, which is why the score is not higher.

Dependency/Withdrawal (3.5/5.0): Dependency here is functional, not addictive. Survodutide does not create cravings or a withdrawal syndrome, but the benefits depend on staying on it. Stop the weekly injection and appetite returns, weight tends to climb back, and any metabolic gains fade, the universal pattern for this class. There is no documented tolerance that forces ever-higher doses, and quitting is not dangerous. But because the result only holds while you keep dosing, the practical reliance is real and lands in the middle of the range.

Reversibility (1.8/5.0): Reversibility is excellent, one of survodutide's genuine strengths. The drug clears the body within a week or so of the last dose, so any unwanted effect resolves cleanly without a taper, and the heart-rate and glucose signals return toward baseline once it is out. Weight regain after stopping is a durability problem, not a reversibility one, because the body simply returns to its prior set point rather than being left permanently changed. There is no evidence of lasting harm from a clean stop, which is exactly what you want from an experimental compound.